Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.
作者信息
Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I
出版信息
Eye (Lond). 2015 Mar;29(3):450-1. doi: 10.1038/eye.2014.321.
Abstract
摘要
相似文献
1
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.新生血管性年龄相关性黄斑变性观察与计划方案的两年结果：如何在维持功能结果的同时减轻临床负担。
Eye (Lond). 2015 Mar;29(3):450-1. doi: 10.1038/eye.2014.321.
2
Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.基于新生血管性年龄相关性黄斑变性初始稳定后视力变化的抗血管内皮生长因子治疗的再治疗：3 年随访结果。
Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.
3
Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.贝伐单抗治疗新生血管性年龄相关性黄斑变性的治疗和延长方案：临床和经济影响。
Am J Ophthalmol. 2012 Mar;153(3):468-473.e1. doi: 10.1016/j.ajo.2011.08.011. Epub 2011 Oct 11.
4
Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.用于治疗新生血管性年龄相关性黄斑变性的贝伐单抗持续给药方案：基线特征的重要性
Retina. 2014 May;34(5):846-52. doi: 10.1097/IAE.0000000000000033.
5
Implementation studies of ranibizumab for neovascular age-related macular degeneration.雷珠单抗治疗新生血管性年龄相关性黄斑变性的应用研究。
Acta Ophthalmol. 2013 Nov;91 Thesis7:1-22. doi: 10.1111/aos.12272.
6
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.贝伐单抗治疗新生血管性年龄相关性黄斑变性（ABC 试验）：多中心随机双盲研究。
BMJ. 2010 Jun 9;340:c2459. doi: 10.1136/bmj.c2459.
7
Bevacizumab for neovascular age-related macular degeneration in China.贝伐单抗治疗中国新生血管性年龄相关性黄斑变性。
Ophthalmology. 2012 Oct;119(10):2087-93. doi: 10.1016/j.ophtha.2012.05.016. Epub 2012 Jul 20.
8
Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.采用治疗并延长方案治疗3年后新生血管性年龄相关性黄斑变性的治疗结果。
Am J Ophthalmol. 2015 Jan;159(1):3-8.e1. doi: 10.1016/j.ajo.2014.09.011. Epub 2014 Sep 8.
9
Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.2004-2008 年 Medicare 受益人群中新诊断的与年龄相关的新生血管性黄斑变性的成本。
Retina. 2013 Apr;33(4):854-61. doi: 10.1097/IAE.0b013e31826f065e.
10
Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.经 ranibizumab 治疗的新生血管性年龄相关性黄斑变性的微视野测量视网膜功能变化。
Am J Ophthalmol. 2013 Jan;155(1):118-126.e1. doi: 10.1016/j.ajo.2012.07.009. Epub 2012 Sep 27.
引用本文的文献
1
Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis.观察与计划疗法治疗新生血管性年龄相关性黄斑变性的长期疗效：一项回顾性真实世界分析
Eye (Lond). 2025 May 10. doi: 10.1038/s41433-025-03830-1.
2
Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.抗血管内皮生长因子治疗的短期反应可作为难治性年龄相关性黄斑变性视预后的指标。
Eye (Lond). 2024 May;38(7):1342-1348. doi: 10.1038/s41433-023-02900-6. Epub 2024 Jan 26.
3
Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration.患者对年龄相关性黄斑变性从治疗和延长方案转换为观察和计划方案后的满意度。
BMJ Open Ophthalmol. 2022 Jan 7;7(1):e000930. doi: 10.1136/bmjophth-2021-000930. eCollection 2022.
4
TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.COVID-19 封锁期间的治疗延迟：对新生血管性年龄相关性黄斑变性患者的功能和解剖影响。
Retina. 2022 Apr 1;42(4):634-642. doi: 10.1097/IAE.0000000000003369.
5
Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections.重新审视散瞳眼底检查在接受定期玻璃体内注射治疗的新生血管性年龄相关性黄斑变性患者中的效用。
Clin Ophthalmol. 2021 Mar 12;15:1129-1131. doi: 10.2147/OPTH.S303551. eCollection 2021.
6
Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere) in patients with neovascular age-related macular degeneration.玻璃体内注射贝伐单抗（Lumiere）治疗新生血管性年龄相关性黄斑变性患者的安全性和临床有效性。
Exp Ther Med. 2020 Dec;20(6):162. doi: 10.3892/etm.2020.9291. Epub 2020 Oct 9.
7
Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.现实生活中成像模态的应用：对德国雷珠单抗治疗新生血管性年龄相关性黄斑变性视力结果的影响
J Ophthalmol. 2020 Jul 16;2020:8024258. doi: 10.1155/2020/8024258. eCollection 2020.
8
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性的黄斑萎缩发生率：根据观察与计划方案个体化治疗雷珠单抗或阿柏西普需求的风险因素评估。
Retina. 2019 May;39(5):906-917. doi: 10.1097/IAE.0000000000002054.
9
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.阿柏西普治疗新生血管性年龄相关性黄斑变性的观察与计划方案的两年结果
Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2127-2134. doi: 10.1007/s00417-017-3762-2. Epub 2017 Aug 10.
10
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.视网膜下液在新生血管性年龄相关性黄斑变性患者治疗结局判定中的作用——一项雷珠单抗的IV期随机临床试验：FLUID研究
BMC Ophthalmol. 2016 Mar 24;16:31. doi: 10.1186/s12886-016-0207-3.
Zotero 插件